Dr Isabel Monteiro dos Santos Pires
Targeting ADAM10 as a novel strategy for radiotherapy enhancement in hypoxic colorectal cancer
People Involved
Dr Louis Allott
Project Description
Radiotherapy remains one of the most effective non-invasive treatments for solid cancers, including bowel cancer. However, specific aspects of the biology of tumours, particularly the presence of low oxygen regions, remain a key limitation for its success. In fact, low-oxygen biology is a well-known driver of resistance to radiotherapy and a marker of poor outcome in most cancers, including bowel cancer.
It has been shown before that ADAM10 has an important role in tumour growth in several cancer types, with pilot data from our group being the first to indicate that ADAM10 can be affected by low oxygen conditions, and can affect the growth of bowel cancer cells in the lab.
In this project we propose to investigate how ADAM10 contributes to the growth of colorectal cancers in low oxygen conditions, and whether targeting it can improve response to radiotherapy. This project has the potential to validate ADAM10 as a target in bowel cancer that could be used in combination with radiotherapy. This could lead to improved quality of life though more effective radiotherapy treatments with reduced side effects, as well as improving therapy responses for bowel cancer patients, especially those with lower oxygen levels present in their tumours.
| Type of Project | Studentship |
|---|---|
| Status | Project Complete |
| Funder(s) | Bowel and Cancer Research |
| Value | £77,076.00 |
| Project Dates | Sep 19, 2021 - Aug 18, 2024 |
You might also like
Impact of CO2 on antigen expression: new ways to induce immune responses against cancer?’ Jul 1, 2019 - Jun 30, 2020
Summer studentship to investigate the impact of CO2 levels on antigens expression in cancer. The study uses state-of-the-art 3D models to replace whole organism studies of hypoxia.
Developing SuFEx "click" chemistry for positron emission tomography (PET) radiochemistry Jan 31, 2022 - May 31, 2023
HPLC purification of GMP PET radiopharmaceuticals in the Molecular Imaging Research Centre (MIRC) Mar 1, 2022 - Feb 28, 2023
Nuclear medicine is a clinical discipline where the unique properties of ionising radiation are harnessed to diagnose and treat diseases like cancer. Positron Emission Tomography (PET) is a medical scan used in nuclear medicine, where a radioactive m...
Read More about HPLC purification of GMP PET radiopharmaceuticals in the Molecular Imaging Research Centre (MIRC).
Radiopharmacy GMP radiotracer production Feb 1, 2023 - Dec 31, 2023
Using a custom-designed spheroid-on chip model to study impact of sheer stress under low oxygen conditions Jul 1, 2022 - Dec 31, 2022
Metastatic, or secondary, cancer has particularly poor prognosis, accounting for up to 90% of all cancer deaths. Therefore, identification and validation of early metastasis biomarkers and/or defining metastasis-specific therapeutic targets is essent...
Read More about Using a custom-designed spheroid-on chip model to study impact of sheer stress under low oxygen conditions.